Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; 14 of the 25 sources its claims cite were checked for support.

CONSORT 2025 statement: Updated guideline for reporting randomised trials

Open access

Abstract

Background: Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. Methods: We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (e.g., personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. Results: We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Conclusions: Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.

Overview

CoChat Summary

TL;DR

CONSORT 2025 is an updated reporting guideline for randomised trial reports, replacing CONSORT 2010 with a 30-item checklist and revised flow diagram. It adds seven items, revises three, deletes one, integrates items from key CONSORT extensions, and introduces an open science section.

Key findings

  • The CONSORT 2025 checklist contains 30 items and includes a new open science section covering trial registration, protocol/statistical analysis plan access, data sharing, and funding/conflicts of interest.
  • The update added seven new checklist items, revised three items, deleted one item, and integrated several items from CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment) and TIDieR.
  • New items address data sharing (item 4), author conflicts of interest (item 5b), patient/public involvement (item 8), site/intervention-deliverer eligibility (item 12b), harms assessment (item 15), analysis populations and missing data (items 21b, 21c), and intervention/comparator delivery and concomitant care (items 24a, 24b).
  • An expanded version of the checklist was developed with bullet points eliciting critical elements of each item.

Methods

  • The update followed EQUATOR Network guidance and used a scoping review, a project-specific database (SCEBdb), and recommendations from lead authors of key CONSORT extensions, TIDieR, and other sources.
  • A three-round international online Delphi survey involved 317 participants in round 1, 303 in round 2, and 290 in round 3; participants rated item inclusion on a 5-point Likert scale.
  • A two-day online expert consensus meeting of 30 invited international experts discussed the Delphi results, followed by a two-day in-person executive writing meeting in Oxford on 25–26 April 2023.

Limitations

  • The paper states that CONSORT 2025 and SPIRIT 2025 do not include recommendations for designing, conducting, or analysing trials, and that CONSORT 2025 is not meant to be used as a quality assessment instrument.
  • The paper states that CONSORT 2025 focuses on the most common two-group parallel design and that existing CONSORT extensions have not yet been aligned with CONSORT 2025; readers are advised to use existing relevant extensions in the meantime.
  • Evident from the text: no formal consensus threshold was specified for the advisory Zoom polls at the expert consensus meeting, and the guideline is described as a living guideline that will be periodically updated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1004587

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 CONSORT 2025 flow diagram. Flow diagram of the progress through the phases of a randomised trial of two groups (i.e., enrolment, intervention allocation, follow-up, and data analysis). CONSORT = Consolidated Standards of Reporting Trials.
Fig 1 CONSORT 2025 flow diagram. Flow diagram of the progress through the phases of a randomised trial of two groups (i.e., enrolment, intervention allocation, follow-up, and data analysis). CONSORT = Consolidated Standards of Reporting Trials.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 5 Not checked · 34 Own results and interpretations

2 more claims

Create a free account to see all 50 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 43
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Citations

Cites

Show all 52 references

Cited by

See all 139

Metadata

Authors
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., Hoffmann, T. C., Ioannidis, J. P. A., Kahan, B. C., Knowles, R. L., Lamb, S. E., Lewis, S., Loder, E., Offringa, M., Ravaud, P., Richards, D. P., Rockhold, F. W., Schriger, D. L., Siegried, N. L., Staniszewska, S., Taylor, R. S., Thabane, L., Torgerson, D., Vohra, S., White, I. R., & Boutron, I.
Affiliations
  • University of Oxford (GB)
  • University of Toronto (CA)
  • University of Southern Denmark (DK)
  • Ottawa Hospital Research Institute (CA)
  • University of North Carolina at Chapel Hill (US)
  • Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
  • Centers for Disease Control and Prevention (US)
  • Rutgers, The State University of New Jersey (US)
  • Society for Applied Studies (IN)
  • University of Aberdeen (GB)
  • Miami University (US)
  • London School of Hygiene & Tropical Medicine (GB)
  • Northwestern University (US)
  • Stanford University (US)
  • Bond University (AU)
  • MRC Clinical Trials Unit at UCL (GB)
  • University College London (GB)
  • University of Exeter (GB)
  • University of Edinburgh (GB)
  • Harvard University (US)
  • Hospital for Sick Children (CA)
  • Inserm (FR)
  • MaRS (CA)
  • Duke Medical Center (US)
  • University of California, Los Angeles (US)
  • University of Warwick (GB)
  • MRC/CSO Social and Public Health Sciences Unit (GB)
  • St. Joseph’s Healthcare Hamilton (CA)
  • University of York (GB)
  • University of Alberta (CA)
Corresponding author
Hopewell, Sally
Venue
PLOS Medicine
Published
2025-04-14
Volume
22
Issue
4
Pages
e1004587
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W4409424632
Cited by
139
References
52
Citations by year
2026: 72 · 2025: 67
FWCI
88.16
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • Bond University Research Portal (Bond University) (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Medical Research Council (MR/W020483/1)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Social Sciences › Sociology and Political Science › Delphi Technique in Research
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
reporting guidelines, randomised trials, trial reporting quality, CONSORT checklist, CONSORT extension, harms reporting, non-pharmacological treatment, open science, flowcharts, TIDieR, Delphi consensus
MeSH terms
Delphi Technique, Humans, Publishing, Research Design, Randomized Controlled Trials as Topic, Guidelines as Topic, Checklist, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CONSORT 2025 statement: Updated guideline for reporting randomised trials. https://app.cochat.ai/papers/10.1371/journal.pmed.1004587
The paper
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., . . . Boutron, I. (2025). CONSORT 2025 statement: Updated guideline for reporting randomised trials. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004587

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.